This Week in Allergy & Immunology — Oct 4, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning biologics and the pursuit of remission in eosinophilic disease, the evolving science of food allergy immunotherapy and natural history, and the residual burden and diagnostic challenges that persist across atopic dermatitis, hereditary angioedema and perioperative reactions. Let's dive in.

Our first theme asks whether biologics do more than control symptoms in eosinophilic disease, and what stands between patients and true remission. The headline comes from the Journal of Allergy and Clinical Immunology, where Porpodis and colleagues report three-year follow-up of the MESILICO study of mepolizumab in severe asthma responders [1]. Of the 47 patients who started mepolizumab, 35 patients completed three years of treatment, with sustained gains in lung function, biomarkers and exacerbation rates. The more provocative data come from repeat bronchoscopy in 25 patients from the sub-study: sub-basement membrane thickness, airway smooth muscle area and epithelial damage all remained significantly reduced from baseline, tissue eosinophils fell, and markers of mucin expression, epithelial integrity and regulatory-like cells improved further at three years. The authors frame this as the first evidence that sustained interleukin-5 blockade may contribute to long-term structural improvement, possibly consistent with disease modification. That is a careful phrasing for good reason: this is an uncontrolled cohort of responders, with substantial attrition at the bronchoscopy stage, so it supports a hypothesis rather than settling it. A counterweight comes from Al-Ahmad and colleagues in the World Allergy Organization Journal [2]. In severe asthma patients assessed with impulse oscillometry and spirometry, small airway dysfunction was common, detected in about two thirds of patients by oscillometry. After a year of biologic therapy, control, exacerbations and lung function improved substantially, yet only about one in six patients met clinical remission criteria, and remission was significantly less frequent among patients with small airway dysfunction. Patients with small airway disease were older and carried more allergic and metabolic comorbidity. Read together, these two papers suggest that biologics can reshape the central airway in good responders while the distal airway may remain a barrier to remission, though both are observational and neither establishes causation. Framing this conversation is an expert review, also in the Journal of Allergy and Clinical Immunology, from Dorscheid and colleagues [3], summarising a London expert group meeting on epithelial health. The group argues that current biomarkers, such as mucus plugs, ventilation defects and cilia beat frequency, only indirectly capture epithelial function, and they make the case for an early treat-to-target approach aimed at restoring epithelial health and achieving remission across the united airway. This is consensus opinion, not trial evidence. Extending the treat-to-target idea beyond asthma, Chevalier and colleagues, in The Journal of Allergy and Clinical Immunology: In Practice, report a French multicentre real-world study of 67 patients with FIP1L1::PDGFRA-negative hypereosinophilic syndrome on long-term mepolizumab [4]. Over a median of about four years, fewer than one in five patients relapsed, and patients spent a median of nearly four fifths of visits in a newly defined eosinophilic low disease activity state, meaning no relapse, eosinophils below 0.5 times ten to the ninth per litre, and prednisone at or below 5 milligrams a day. Poor attainment clustered in lymphocytic variant disease and in heavily pretreated patients. Extending dosing intervals nudged eosinophil counts up modestly without increasing relapse or steroid exposure, and no serious adverse event was attributed to the drug. The retrospective design and the need for prospective validation of the new definition both limit how far this can go, but it offers a pragmatic longitudinal yardstick.

Our second theme turns to food allergy, where three papers address how to make oral immunotherapy safer and more efficient, and who outgrows allergy on their own. In Allergy, Simard and colleagues report a small phase 2a trial of abatacept, the CTLA-4 fusion protein, as an adjunct to peanut oral immunotherapy in 14 adults and adolescents with very high peanut-specific IgE [5]. The primary outcome was negative: abatacept did not significantly suppress the immunotherapy-induced rise in the ratio of peanut-specific to total IgE at 24 weeks. Minimal reactive doses after four weeks of avoidance were similar in both groups. The signal of interest was tolerability, with significantly fewer adverse events, including anaphylaxis, in the abatacept arm, and most participants in both arms achieved sustained unresponsiveness regardless of abatacept. With only 14 participants, this is hypothesis-generating at best, but it is notable that oral immunotherapy alone performed well in a severely allergic adult population. From Pediatric Allergy and Immunology, Koren and colleagues tackle walnut and hazelnut co-allergy in the nut CRACKER study [6]. Among 22 co-allergic patients fully desensitised to walnut, just over half of patients became fully cross-desensitised to hazelnut, and nearly two thirds of patients were clinically cross-desensitised. Competitive inhibition assays at baseline separated the two groups: walnut blocked hazelnut IgE binding by a median of about 95 percent in patients who cross-desensitised, versus about 55 percent in those who stayed allergic, and a threshold of 70 percent inhibition predicted the outcome in 93 percent of cases. This is a small single-centre cohort, and the assay is not routinely available, but it points toward choosing a single nut for immunotherapy based on molecular cross-reactivity. Also in Pediatric Allergy and Immunology, Goto and colleagues describe the natural history of peanut allergy in 42 Japanese children diagnosed by age three and followed with stepwise food challenges [7]. Tolerance was rare early, at about 2 percent by age four, rising to roughly a third of children by age twelve. Lower peanut-specific IgE at age three, with a median near 4 versus about 28 kilounits per litre, was associated with later tolerance, as were lower Ara h 2 levels at six and nine years. The small sample and a high proportion of boys limit generalisability, but the challenge-confirmed outcomes add weight to the view that most early peanut allergy persists into later childhood.

Our final theme gathers papers on predicting persistence, residual burden and diagnostic rigour across other allergic conditions. In Allergology International, Kojima and colleagues analysed 1,769 children from the Yamanashi adjunct of the Japan Environment and Children's Study [8]. Palmar hyperlinearity, a minor Hanifin and Rajka criterion linked to filaggrin loss-of-function variants, was uncommon at about 2 percent, but it was associated with roughly three and a half times the odds of a persistent atopic dermatitis trajectory, and not with early-onset or late-onset patterns. An artificial intelligence based assessment gave similar results, and the persistent trajectory itself was tied to food allergy, asthma, rhinitis and later sensitisation. The finding is observational and based on few affected children, but it suggests a simple bedside sign may flag a higher-risk phenotype. In the World Allergy Organization Journal, Greve and colleagues used German insurance claims and chart review to describe long-term prophylaxis in hereditary angioedema [9]. Among 77 patients starting prophylaxis, intravenous C1 inhibitor and lanadelumab were most common, and about a third of patients switched therapy, usually from intravenous C1 inhibitor to lanadelumab. Despite prophylaxis, close to two thirds of patients had at least one attack requiring on-demand treatment in the first year, and annual costs exceeded 200,000 euros per person, driven by medication. Claims data cannot capture attack severity, but the residual burden is a reminder that prophylaxis rarely eliminates attacks. Finally, in Current Allergy and Asthma Reports, Ebo and colleagues review perioperative hypersensitivity [10], highlighting neuromuscular blocking agents, antibiotics, latex and chlorhexidine as leading culprits, and arguing for a stepwise strategy combining in vitro assays, skin testing, basophil and mast cell activation tests and selective drug provocation, particularly when conventional testing is inconclusive. This is an expert narrative review rather than new data.

If you only have time for one paper this week, make it the three-year MESILICO bronchoscopy follow-up from Porpodis and colleagues [1]. It reopens the question of whether anti-interleukin-5 therapy can genuinely modify airway structure in severe eosinophilic asthma, rather than simply suppressing inflammation, while leaving that question for controlled studies to settle.

Here is what this week's evidence adds up to in Allergy & Immunology. First, long-term mepolizumab is associated with sustained structural airway improvement in severe asthma responders and durable low disease activity in FIP1L1::PDGFRA-negative hypereosinophilic syndrome, but both datasets are uncontrolled and observational. Second, clinical remission on biologics remains uncommon in severe asthma, and small airway dysfunction emerges as one measurable barrier, a finding from a single observational cohort that has not yet entered remission definitions. Third, in food allergy, abatacept failed its primary IgE outcome while hinting at better tolerability in a very small trial, and molecular inhibition testing may predict cross-desensitisation from walnut to hazelnut, both early-stage findings. Fourth, challenge-confirmed data show that only about a third of children with early peanut allergy outgrow it by age twelve, with lower early IgE pointing to better odds. Finally, residual attacks remain common in hereditary angioedema despite prophylaxis, and palmar hyperlinearity may mark a persistent atopic dermatitis phenotype, both observations that warrant prospective confirmation.

That's your roundup for This Week in Allergy & Immunology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.